Trial Profile
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs IMC CS4 (Primary)
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Sarcoma; Solid tumours
- Focus First in man; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 23 Feb 2021 Results published in the Investigational New Drugs
- 20 Jul 2018 Status changed from active, no longer recruiting to completed.
- 15 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.